×
About 650 results

ALLMedicine™ Erythroleukemia Center

Research & Reviews  325 results

LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcripti...
https://doi.org/10.1182/bloodadvances.2020003521
Blood Advances; Kohrogi K, Hino S et. al.

Apr 30th, 2021 - Acute myeloid leukemia (AML) is a heterogenous malignancy characterized by distinct lineage subtypes and various genetic/epigenetic alterations. As with other neoplasms, AML cells have well-known aerobic glycolysis, but metabolic variations depend...

Synergistic effects of LY294002 and ABT199 on the cell cycle in K562, HL60 and KG1a cells.
https://doi.org/10.3892/or.2021.8048
Oncology Reports; Geng Y, Wu W et. al.

Apr 13th, 2021 - The aim of the present study was to investigate the synergistic effect of LY294002 (a PI3K inhibitor) and ABT199 (a BCL2 inhibitor) on the cell cycle in acute myeloid leukemia (AML). The optimal concentration and duration of combined LY294002 and ...

Modeling and targeting of erythroleukemia by hematopoietic genome editing.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995291
Blood Iacobucci I, Qu C et. al.

Jan 29th, 2021 - Acute erythroid leukemia (AEL) is characterized by a distinct morphology, mutational spectrum, lack of preclinical models, and poor prognosis. Here, using multiplexed genome editing of mouse hematopoietic stem and progenitor cells and transplant a...

5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expressi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925369
Molecular Cancer Research : MCR; Reilly BM, Luger T et. al.

Nov 11th, 2020 - DNA methyltransferase inhibitors (DNMTI) like 5-Azacytidine (5-Aza) are the only disease-modifying drugs approved for the treatment of higher-risk myelodysplastic syndromes (MDS), however less than 50% of patients respond, and there are no predict...

see more →

Clinicaltrials.gov  325 results

LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcripti...
https://doi.org/10.1182/bloodadvances.2020003521
Blood Advances; Kohrogi K, Hino S et. al.

Apr 30th, 2021 - Acute myeloid leukemia (AML) is a heterogenous malignancy characterized by distinct lineage subtypes and various genetic/epigenetic alterations. As with other neoplasms, AML cells have well-known aerobic glycolysis, but metabolic variations depend...

Synergistic effects of LY294002 and ABT199 on the cell cycle in K562, HL60 and KG1a cells.
https://doi.org/10.3892/or.2021.8048
Oncology Reports; Geng Y, Wu W et. al.

Apr 13th, 2021 - The aim of the present study was to investigate the synergistic effect of LY294002 (a PI3K inhibitor) and ABT199 (a BCL2 inhibitor) on the cell cycle in acute myeloid leukemia (AML). The optimal concentration and duration of combined LY294002 and ...

Modeling and targeting of erythroleukemia by hematopoietic genome editing.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995291
Blood Iacobucci I, Qu C et. al.

Jan 29th, 2021 - Acute erythroid leukemia (AEL) is characterized by a distinct morphology, mutational spectrum, lack of preclinical models, and poor prognosis. Here, using multiplexed genome editing of mouse hematopoietic stem and progenitor cells and transplant a...

5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expressi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925369
Molecular Cancer Research : MCR; Reilly BM, Luger T et. al.

Nov 11th, 2020 - DNA methyltransferase inhibitors (DNMTI) like 5-Azacytidine (5-Aza) are the only disease-modifying drugs approved for the treatment of higher-risk myelodysplastic syndromes (MDS), however less than 50% of patients respond, and there are no predict...

see more →